Market Closed -
Nyse
04:10:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
0.42
USD
|
+0.12%
|
|
+2.19%
|
-2.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8.519
|
7.657
|
35.94
|
6.878
|
7.33
|
7.202
|
-
|
-
|
Enterprise Value (EV)
1 |
8.519
|
7.657
|
35.94
|
6.878
|
7.33
|
7.202
|
7.202
|
7.202
|
P/E ratio
|
-0.52
x
|
-0.58
x
|
-1.43
x
|
-0.35
x
|
-0.38
x
|
-0.52
x
|
-0.55
x
|
-0.63
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,681
|
1,999
|
13,204
|
15,124
|
17,043
|
17,148
|
-
|
-
|
Reference price
2 |
5.069
|
3.830
|
2.722
|
0.4548
|
0.4301
|
0.4200
|
0.4200
|
0.4200
|
Announcement Date
|
2/20/20
|
3/4/21
|
3/16/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.66
|
-10.16
|
-14.27
|
-21.58
|
-21.43
|
-28.57
|
-34.29
|
-37.13
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-10.12
|
-14.27
|
-21.11
|
-19.99
|
-28.57
|
-34.29
|
-37.13
|
Net income
1 |
-16.08
|
-12.56
|
-23.19
|
-19.68
|
-18.35
|
-28.57
|
-34.29
|
-37.13
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-9.800
|
-6.600
|
-1.900
|
-1.310
|
-1.140
|
-0.8100
|
-0.7600
|
-0.6700
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
3/4/21
|
3/16/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.275
|
-5.265
|
-
|
-4.985
|
-5.014
|
-7.33
|
-5.178
|
-5.82
|
-4.218
|
-6.217
|
-6.572
|
-6.857
|
-7.429
|
-7.715
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.273
|
-5.263
|
-
|
-4.968
|
-4.853
|
-7.016
|
-4.808
|
-5.443
|
-3.83
|
-5.909
|
-6.572
|
-6.857
|
-7.429
|
-7.715
|
Net income
1 |
-3.273
|
-5.263
|
-
|
-4.968
|
-4.853
|
-5.591
|
-4.478
|
-5.084
|
-3.303
|
-5.485
|
-6.572
|
-6.857
|
-7.429
|
-7.715
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2000
|
-0.4000
|
-
|
-0.3100
|
-0.3300
|
-0.3600
|
-0.3000
|
-0.3400
|
-0.1900
|
-0.3300
|
-0.1900
|
-0.1900
|
-0.2100
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/16/22
|
5/16/22
|
8/11/22
|
11/10/22
|
3/30/23
|
5/11/23
|
8/8/23
|
11/13/23
|
3/25/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
3/4/21
|
3/16/22
|
3/30/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
0.42
USD Average target price
4.5
USD Spread / Average Target +971.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.35% | 7.2M | | -2.63% | 102B | | +1.62% | 96.29B | | +1.72% | 22.18B | | -16.67% | 21.2B | | -8.65% | 18.31B | | -38.74% | 17.38B | | -13.21% | 16.36B | | +5.41% | 13.97B | | +33.57% | 12.17B |
Bio Therapeutic Drugs
|